- Home
- DCI vs LEGN Comparison
DCI vs LEGN Comparison
Compare DCI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- LEGN
- Stock Information
- Founded
- DCI 1915
- LEGN 2014
- Country
- DCI United States
- LEGN United States
- Employees
- DCI N/A
- LEGN N/A
- Industry
- DCI Pollution Control Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- LEGN Health Care
- Exchange
- DCI Nasdaq
- LEGN Nasdaq
- Market Cap
- DCI 7.9B
- LEGN 7.0B
- IPO Year
- DCI 1987
- LEGN 2020
- Fundamental
- Price
- DCI $69.73
- LEGN $27.80
- Analyst Decision
- DCI Hold
- LEGN Strong Buy
- Analyst Count
- DCI 4
- LEGN 13
- Target Price
- DCI $71.33
- LEGN $75.67
- AVG Volume (30 Days)
- DCI 461.7K
- LEGN 1.6M
- Earning Date
- DCI 06-03-2025
- LEGN 05-13-2025
- Dividend Yield
- DCI 1.55%
- LEGN N/A
- EPS Growth
- DCI 11.79
- LEGN N/A
- EPS
- DCI 3.42
- LEGN N/A
- Revenue
- DCI $3,633,400,000.00
- LEGN $728,303,000.00
- Revenue This Year
- DCI $2.95
- LEGN $65.96
- Revenue Next Year
- DCI $3.44
- LEGN $52.55
- P/E Ratio
- DCI $20.40
- LEGN N/A
- Revenue Growth
- DCI 4.46
- LEGN 112.46
- 52 Week Low
- DCI $57.45
- LEGN $29.27
- 52 Week High
- DCI $78.95
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- DCI 64.33
- LEGN 29.31
- Support Level
- DCI $65.72
- LEGN $30.25
- Resistance Level
- DCI $70.80
- LEGN $33.30
- Average True Range (ATR)
- DCI 0.99
- LEGN 1.72
- MACD
- DCI 0.62
- LEGN -0.41
- Stochastic Oscillator
- DCI 83.66
- LEGN 3.14
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.